Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096718 | 1.00 | MMP13 (0.41) | MMP13MTORNR4A2CTSSCTSK | |
| SCHEMBL1096720 | 1.00 | MMP13 (0.41) | MMP13MTORNR4A2CTSSCTSK | |
| SCHEMBL15723420 | 0.88 | SRC (0.36) | MMP13CTSSCTSKL3MBTL1SRC | |
| SCHEMBL26409828 | 0.88 | TRPM8 (0.44) | MMP13MTORCTSSCTSKGAA | |
| SCHEMBL20556352 | 0.88 | SRC (0.36) | MMP13CTSSCTSKL3MBTL1SRC | |
| SCHEMBL25169590 | 0.86 | TXNRD1 (0.36) | MMP13CTSSCTSKGAAHTT | |
| SCHEMBL1096980 | 0.86 | KMT2A (0.47) | MMP13MTORCTSSCTSKNR1H2 | |
| SCHEMBL25169591 | 0.86 | TXNRD1 (0.36) | MMP13CTSSCTSKGAAHTT | |
| SCHEMBL1096979 | 0.86 | KMT2A (0.47) | MMP13MTORCTSSCTSKNR1H2 | |
| SCHEMBL30466250 | 0.85 | NPSR1 (0.42) | MMP13L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| WO-2011011483-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20080319008-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| EP-1765347-A4 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | UNIV CALIFORNIA (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1765347-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | The Regents of the University of California (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005120497-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-6649606-B1 | Treating inflammatory diseases | BRISTOL-MYERS SQUIBB CO. | 2003-11-18 | — | — | US | disclosed |
| WO-2003041641-A2 | TETRAHYDROISOQUINOLINE ANALOGS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | MMP13 4015/4885MTOR 269/4885NR4A2 4078/4885 |
| US-20080319008-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | CFTR, ABCC9, SLC26A4 | MMP13 3547/4885MTOR 2725/4885NR4A2 4425/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | MMP13 3961/4885MTOR 187/4885NR4A2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.